Pazopanib-d6
- Product Name
- Pazopanib-d6
- CAS No.
- 1219592-01-4
- Chemical Name
- Pazopanib-d6
- Synonyms
- Pazopanib-d6;2H6]-Pazopanib;2-methyl-5-[[4-[methyl-d3-[3-methyl-2-(methyl-d3)-2H-indazol-6-yl]amino]-2-pyrimidinyl]amino]-benzenesulfonamide;2-methyl-5-({4-[(2H?)methyl[2-(2H?)methyl-3-methyl-2H-indazol-6-yl]amino]pyrimidin-2-yl}amino)benzene-1-sulfonamide
- CBNumber
- CB72741889
- Molecular Formula
- C21H23N7O2S
- Formula Weight
- 437.52
- MOL File
- 1219592-01-4.mol
Pazopanib-d6 Property
- storage temp.
- Store at -20°C
- solubility
- DMF: 16 mg/ml; DMSO: 16 mg/ml
- form
- A solid
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- 25446
- Product name
- Pazopanib-d6
- Purity
- ≥99% deuterated forms (d1-d6)
- Packaging
- 500μg
- Price
- $290
- Updated
- 2024/03/01
- Product number
- 25446
- Product name
- Pazopanib-d6
- Purity
- ≥99% deuterated forms (d1-d6)
- Packaging
- 1mg
- Price
- $549
- Updated
- 2024/03/01
- Product number
- 3396DH
- Product name
- 2-Methyl-5-[[4-[[3-methyl-2-(trideuteriomethyl)indazol-6-yl]-(trideuteriomethyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide
- Packaging
- 1mg
- Price
- $710
- Updated
- 2021/12/16
Pazopanib-d6 Chemical Properties,Usage,Production
Description
Pazopanib-d6 is intended for use as an internal standard for the quantification of pazopanib by GC- or LC-MS. Pazopanib is a multi-kinase inhibitor that inhibits the VEGF receptors VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively, in a cell-free enzyme assay).1 It also inhibits PDGFRα, PDGFRβ, and c-Kit (IC50s = 71, 84, and 74 nM, respectively, in a cell-free enzyme assay) as well as additional receptor tyrosine kinases. Pazopanib inhibits upregulation of the surface adhesion proteins ICAM-1 and VCAM-1 induced by VEGF in multiple myeloma cells cocultured with human umbilical vein endothelial cells (HUVECs) and decreases multiple myeloma cell adhesion to HUVECs.2 It also inhibits proliferation of multiple myeloma cells cocultured with HUVECs. Pazopanib (30 and 100 mg/kg) reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model. Formulations containing pazopanib have been used in the treatment of cancer.
References
1. Kumar, R., Knick, V.B., Rudolph, S.K., et al. Pharmacokinetic-
2. Podar, K., Tonon, G., Satler, M., et al. The small-